Xenon Pharmaceuticals has appointed Ian Mortimer as chief financial officer.
Mortimer will join Xenon on November 1, 2013. He has more than 15 years’ experience in the biotechnology sector.
Currently with Tekmira Pharmaceuticals Corporation, as executive VP and chief financial officer, Mortimer is responsible for all aspects of the company’s finance and capital markets activities and led Tekmira’s listing on Nasdaq in 2010.
Prior to joining Tekmira, Mortimer was chief financial officer at Inex Pharmaceuticals Corporation. He has an MBA from Queen’s University, a BSc in microbiology from the University of British Columbia and is a Certified Management Accountant.
“We are delighted to welcome Ian to the team. He brings a combination of strong financial and operations experience that is highly relevant to Xenon,” said Dr Simon Pimstone, Xenon’s president and CEO.
“Given our pipeline of approved, development stage and discovery stage products and programmes, together with our strong balance sheet and our suite of major pharmaceutical partnerships, this is a good time for Xenon to be adding an experienced CFO like Ian to the company,” Pimstone added.